Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Warner Chilcott Ovcon 35 Launch Delayed By Bristol Manufacturing

This article was originally published in The Pink Sheet Daily

  • News
  • Lee Kalowski

Executive Summary

This is the second launch delay for the chewable oral contraceptive. Warner Chilcott expects to transfer manufacturing of Ovcon from Bristol to a recently-acquired Pfizer plant.

You may also be interested in...



Barr Will Launch Generic Ovcon 35 In October After Regaining Rights To ANDA

Under pressure from FTC, Warner Chilcott ends an exclusive agreement which was blocking Barr entry until May 2009.

Barr Will Launch Generic Ovcon 35 In October After Regaining Rights To ANDA

Under pressure from FTC, Warner Chilcott ends an exclusive agreement which was blocking Barr entry until May 2009.

FTC, States Sue Barr, Warner Chilcott Over Ovcon-35 Deal

Lawsuit claims companies' agreement regarding generic Ovcon-35 was anti-competitive.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS060283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By